TME Pharma N.V. (EPA:ALTME)
France
· Delayed Price · Currency is EUR 0.0706
-0.0029 (-3.95%)
Mar 6, 2026, 5:02 PM CET
TME Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 0.03 | - | - | - | - | - | Upgrade
|
| Other Revenue | - | - | - | - | 0.03 | 0.04 | Upgrade
|
| Revenue | 0.03 | - | - | - | 0.03 | 0.04 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | -5.71% | -77.27% | Upgrade
|
| Gross Profit | 0.03 | - | - | - | 0.03 | 0.04 | Upgrade
|
| Selling, General & Admin | 2.31 | 2.98 | 2.99 | 3.88 | 2.88 | 1.88 | Upgrade
|
| Research & Development | 2.21 | 2.3 | 2.65 | 8.15 | 10.66 | 4.02 | Upgrade
|
| Other Operating Expenses | -0.03 | -0.02 | -0.02 | -0.02 | -0.04 | -0.04 | Upgrade
|
| Operating Expenses | 4.49 | 5.26 | 5.62 | 12.01 | 13.49 | 5.86 | Upgrade
|
| Operating Income | -4.46 | -5.26 | -5.62 | -12.01 | -13.46 | -5.82 | Upgrade
|
| Interest Expense | -0.05 | -0.02 | -0.02 | -0.13 | -0.05 | -0.13 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | 0.01 | 0.01 | -0.03 | 0.18 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.12 | -0.45 | -1.34 | -3.27 | -1.42 | -4.92 | Upgrade
|
| EBT Excluding Unusual Items | -4.63 | -5.72 | -6.97 | -15.45 | -14.74 | -10.86 | Upgrade
|
| Other Unusual Items | 0.06 | - | 0.24 | 0.32 | 0.29 | 0.45 | Upgrade
|
| Pretax Income | -4.58 | -5.72 | -6.73 | -15.13 | -14.45 | -10.41 | Upgrade
|
| Income Tax Expense | - | - | 0 | 0.01 | 0 | - | Upgrade
|
| Earnings From Continuing Operations | -4.58 | -5.72 | -6.74 | -15.13 | -14.45 | -10.41 | Upgrade
|
| Minority Interest in Earnings | - | - | - | 0 | 0 | 0 | Upgrade
|
| Net Income | -4.58 | -5.72 | -6.74 | -15.13 | -14.45 | -10.41 | Upgrade
|
| Net Income to Common | -4.58 | -5.72 | -6.74 | -15.13 | -14.45 | -10.41 | Upgrade
|
| Shares Outstanding (Basic) | 69 | 36 | 5 | 1 | 1 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 69 | 36 | 5 | 1 | 1 | 0 | Upgrade
|
| Shares Change (YoY) | 307.74% | 616.96% | 326.62% | 78.28% | 103.92% | 190.00% | Upgrade
|
| EPS (Basic) | -0.07 | -0.16 | -1.34 | -12.86 | -21.90 | -32.16 | Upgrade
|
| EPS (Diluted) | -0.07 | -0.16 | -1.34 | -12.86 | -21.90 | -32.16 | Upgrade
|
| Free Cash Flow | -4.77 | -4.65 | -5.65 | -12.16 | -12.4 | -5.26 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | -0.13 | -1.13 | -10.34 | -18.79 | -16.27 | Upgrade
|
| Gross Margin | 100.00% | - | - | - | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -16511.11% | - | - | - | -40790.91% | -16640.00% | Upgrade
|
| Profit Margin | -16948.15% | - | - | - | -43793.94% | -29728.57% | Upgrade
|
| Free Cash Flow Margin | -17670.37% | - | - | - | -37560.61% | -15037.14% | Upgrade
|
| EBITDA | -4.5 | -5.24 | -5.59 | -11.99 | -13.44 | -5.81 | Upgrade
|
| D&A For EBITDA | -0.04 | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 | Upgrade
|
| EBIT | -4.46 | -5.26 | -5.62 | -12.01 | -13.46 | -5.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.